Loading
Life sciences · Journal article
Frontiers in Medicine · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [ 177 Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival (rPFS) establishing PSMA-targeted RLT as a key treatment option in advanced disease. Prostate-specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) plays a central role in patient selection, treatment monitoring, and prognostic stratification, thereby supporting a precision oncology approach. More recently, the clinical development of PSMA-targeted radioligand therapy (RLT) has expanded in several directions, including its use in earlier disease stage, such as metastatic hormone-sensitive prostate cancer (mHSPC), and in the neoadjuvant and oligometastatic settings, as well as its integration into multimodal treatment strategies. These include combination approaches with androgen receptor pathway inhibitors (ARPIs), chemotherapy, immunotherapy, and radiation therapy. This review provides a comprehensive overview of the major developments in the field, including advances in molecular imaging, emerging therapeutic indications, combination approaches, and future directions in PSMA-targeted theranostics according to recent clinical trial data. Collectively, these developments highlight the evolving role of beta-emitting RLT across the prostate cancer disease.